Deisy Segura-Villalobos

Dr. Deisy Segura-Villalobos

CINVESTAV
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
Deisy Segura-VillalobosDeisy Segura-Villalobos
Deisy Segura-Villalobos
IRItzel G. Ramírez-Moreno
Itzel G. Ramírez-Moreno
LALizbeth Magnolia Martinez Aguilar
Lizbeth Magnolia Martinez Aguilar
Alfredo Ibarra-SánchezAlfredo Ibarra-Sánchez
Alfredo Ibarra-Sánchez
J. Omar Muñoz-BelloJ. Omar Muñoz-Bello
J. Omar Muñoz-Bello
CGClaudia González-Espinosa
Claudia González-Espinosa
Mast cells (MCs) are tissue-resident immune cells that are important players in diseases associated with chronic inflammation such as cancer. Since MCs can infiltrate solid tumors and promote or limit tumor growth, a possible polarization of MCs to pro-tumoral or anti-tumoral phenotypes has been proposed and remains as a challenging research field. Here, we review the recent evidence regarding the complex relationship between MCs and tumor cells. In particular, we consider: (1) the multifaceted role of MCs on tumor growth suggested by histological analysis of tumor biopsies and studies performed in MC-deficient animal models; (2) the signaling pathways triggered by tumor-derived chemotactic mediators and bioactive lipids that promote MC migration and modulate their function inside tumors; (3) the possible phenotypic changes on MCs triggered by prevalent conditions in the tumor microenvironment (TME) such as hypoxia; (4) the signaling pathways that specifically lead to the production of angiogenic factors, mainly VEGF; and (5) the possible role of MCs on tumor fibrosis and metastasis. Finally, we discuss the novel literature on the molecular mechanisms potentially related to phenotypic changes that MCs undergo into the TME and some therapeutic strategies targeting MC activation to limit tumor growth.

4 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
Zyanya EspinosaZyanya Espinosa
Zyanya Espinosa
Deisy Segura-VillalobosDeisy Segura-Villalobos
Deisy Segura-Villalobos
IRItzel G. Ramírez-Moreno
Itzel G. Ramírez-Moreno
MRMarian Jesabel Pérez Rodríguez
Marian Jesabel Pérez Rodríguez
MLMonica Lamas
Monica Lamas
CGClaudia González-Espinosa
Claudia González-Espinosa
Mast cells (MCs) constitute an essential cell lineage that participates in innate and adaptive immune responses and whose phenotype and function are influenced by tissue-specific conditions. Their mechanisms of activation in type I hypersensitivity reactions have been the subject of multiple studies, but the signaling pathways behind their activation by innate immunity stimuli are not so well described. Here, we review the recent evidence regarding the main molecular elements and signaling pathways connecting the innate immune receptors and hypoxic microenvironment to cytokine synthesis and the secretion of soluble or exosome-contained mediators in this cell type. When known, the positive and negative control mechanisms of those pathways are presented, together with their possible implications for the understanding of mast cell-driven chronic inflammation. Finally, we discuss the relevance of the knowledge about signaling in this cell type in the recognition of MCs as central elements on innate immunity, whose remarkable plasticity converts them in sensors of micro-environmental discontinuities and controllers of tissue homeostasis.

19 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
Deisy Segura-VillalobosDeisy Segura-Villalobos
Deisy Segura-Villalobos
MLMonica Lamas
Monica Lamas
CGClaudia González-Espinosa
Claudia González-Espinosa
Mast cells (MCs) play important roles in tumor development, executing pro- or antitumoral functions depending on tumor type and tumor microenvironment (TME) conditions. Cyclic hypoxia (cyH) is a common feature of TME since tumor blood vessels fail to provide a continuous supply of oxygen to the tumor mass. Here, we hypothesized that the localization of MCs in cyH regions within solid tumors could modify their transcriptional profile and activation parameters. Using confocal microscopy, we found an important number of MCs in cyH zones of murine melanoma B16-F1 tumors. Applying microarray analysis to examine the transcriptome of murine bone-marrow-derived MCs (BMMCs) exposed to interleaved cycles of hypoxia and re-oxygenation, we identified altered expression of 2512 genes. Functional enrichment analysis revealed that the transcriptional signature of MCs exposed to cyH is associated with oxidative phosphorylation and the FcεRI signaling pathway. Interestingly, FcεRI-dependent degranulation, calcium mobilization, and PLC-γ activity, as well as Tnf-α, Il-4, and Il-2 gene expression after IgE/antigen challenge were increased in BMMCs exposed to cyH compared with those maintained in normoxia. Taken together, our findings indicate that cyH causes an important phenotypic change in MCs that should be considered in the design of inflammation-targeted therapies to control tumor growth.

7 February 2020 in TIP Revista Especializada en Ciencias Químico-Biológicas
Verified
Journal Article
Open access
PDF file
DÁDulce Ávila-Rodríguez
Dulce Ávila-Rodríguez
Deisy Segura-VillalobosDeisy Segura-Villalobos
Deisy Segura-Villalobos
AIAlfredo Ibarra-Sánchez
Alfredo Ibarra-Sánchez
CGClaudia González-Espinosa
Claudia González-Espinosa
MMMarina Macías-Silva
Marina Macías-Silva
El Factor de crecimiento transformante β (TGF-β) es una citocina pleiotrópica implicada en distintas condiciones patológicas, como desórdenes autoinmunes, alergias y en los últimos años, en el cáncer. Esta citocina ejerce efectos supresores de tumores que las células cancerosas deben evadir para lograr la progresión del tumor. Sin embargo, paradójicamente, el TGF-β también modula procesos inflamatorios que favorecen la progresión del tumor, como el reclutamiento de células del sistema inmune al sitio del mismo; entre estas células se encuentran las células cebadas (CCs), las cuales, a su vez también participan en la regulación del tumor, a través de la secreción de distintos mediadores proinflamatorios, proangiogénicos y factores de crecimiento. En esta revisión se describen algunos avances en la comprensión del papel del TGF-β en la regulación de las CCs y la contribución de éstas en el desarrollo y la metástasis de tumores sólidos. El entendimiento de la función del TGF-β y de las células cebadas durante el desarrollo del cáncer es fundamental para el diseño de nuevas terapias que inhiban la progresión del tumor.

Verified
Journal Article
Open access
PDF file
DRDulce Ávila Rodríguez
Dulce Ávila Rodríguez
Alfredo Ibarra-SánchezAlfredo Ibarra-Sánchez
Alfredo Ibarra-Sánchez
MSMarcela Sosa-Garrocho
Marcela Sosa-Garrocho
GVGenaro Vázquez-Victorio
Genaro Vázquez-Victorio
CCCassandre Caligaris
Cassandre Caligaris
MMMarina Macias
Marina Macias
TGF-β is a pleiotropic cytokine with both stimulatory and inhibitory effects on immune cells, depending on the microenvironmental context. It targets mast cells (MCs) in different physio-pathological conditions, such as inflammation and cancer. Besides acting as a potent chemoattractant for MCs, TGF-β regulates many other aspects of MCs’ physiology, including the secretion of many regulatory molecules. MCs secrete a variety of mediators, either pre-formed or newly synthesized, upon appropriate stimulation. CCL-2 chemokine and TNF cytokine act as potent chemoattractants for several immune cells and participate in the initiation of inflammatory responses by recruiting them to injured tissues. TGF-β regulates CCL-2 and TNF secretion in different cell types and under distinct cellular contexts. Here, we report that the treatment with TGF-β alone induces the secretion of both pre-formed and newly synthesized CCL-2 in the rat RBL-2H3 mast cells but not in mouse bone marrow-derived mast cells (BMMCs). TGF-β-induced CCL-2 secretion depends on rapid rearrangements of the actin cytoskeleton and, remarkably, on the early secretion of soluble TNF that triggers an autocrine TNF signaling. In conclusion, we found cooperation between TGF-β and TNF signaling pathways to promote the secretion of CCL-2 chemokine by MCs in a cell-context specific manner.

28 September 2026 in Cancer Cell
Verified
Journal Article
Closed access
AAAnna Adam-Artigues
Anna Adam-Artigues
Deisy Segura-VillalobosDeisy Segura-Villalobos
Deisy Segura-Villalobos
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso